Deliver Your News to the World

Mammoth Biosciences Co-Founders Trevor Martin, Janice Chen, and Lucas Harrington Named to 2018 Forbes’ 30 Under 30

Recognized for using CRISPR to democratize disease detection, the founders were named among the most influential millennial professionals in healthcare


Mammoth Biosciences has today had three of its five co-founders recognized among the most influential healthcare innovators under the age of 30 by Forbes. The new Forbes 30 Under 30 Class features co-founders Trevor Martin, CEO (29), Janice Chen, Chief Research Officer (27), and Lucas Harrington, Chief Discovery Officer (27). 

Forbes recognizes that Mammoth has found a niche in the healthcare industry by making diagnostic tests more readily available, even outside a hospital setting. Mammoth is developing the first CRISPR-based platform for disease detection and aims to develop disposable tests capable of detecting multiple diseases based on DNA and RNA. The company’s co-founders recognized the power of using CRISPR, normally used for gene-editing, as a genetic search engine. This application offers enormous potential in disease detection and across other industries such as agriculture and beyond.

“At Mammoth, we’re leveraging CRISPR diagnostics to democratize access to individual’s molecular information. We believe that tackling this issue of access will be a big step in fixing a broken healthcare system,” said Trevor Martin, CEO and co-founder of Mammoth Biosciences. “We are humbled to be recognized as honorees of Forbes’ 30 under 30 and this further solidifies the importance of investing efforts in diagnostics, to offer earlier interventions.”

This award comes on the heels of an exciting year for the company. Mammoth launched in April, then shortly following announced $23 million in funding with participation from top investors including Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital. The company plans to use the funds to expand the team, build out it’s IP portfolio, and focus on developing the CRISPR-based platform for commercialization.

About Mammoth Biosciences:

Mammoth Biosciences is a biotech company that has developed the world’s first and only CRISPR-based detection platform capable of sensing any biomarker or disease with DNA/RNA. The company is co-founded by CRISPR pioneer Jennifer Doudna, Stanford PhDs Trevor Martin and Ashley Tehranchi, and Berkeley PhD students Janice Chen and Lucas Harrington. Mammoth is on a mission to leverage the power of CRISPR to democratize disease detection by bringing accurate and affordable testing out of the laboratory and into the point-of-care. The company’s funding was led by top investors and includes Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital. For more information visit


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.